Abstract: The present invention relates to the art of organic chemistry. The novel compounds - ethyl-3-(2-ethyl-2,2-dimethylhydrazinium)-propionate salts have the general formula: ##STR1## wherein X is Cl, Br, I. The compounds of the present invention possess an antiarrhythmic effect.

Abstract: Novel compounds, viz. 3-(2,2,2-trisubstituted hydrazinium) propionates have the following general formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are an alkyl, a substituted alkyl, a substituted or unsubstituted aryl, an aralkyl or an unsaturated alkyl;R.sup.4, R.sup.5 are hydrogen or a lower alkyl; n is 0 to 2, except for the case where R.sup.1, R.sup.2 and R.sup.3 are methyl, R.sup.4 and R.sup.5 are not hydrogen.The compounds of the present invention possess both hypotensive and antiarrhythmic activity and are useful in medicine.

Abstract: The pharmaceutical composition possessing antitumor activity against tumors susceptible to 2-carbamoylaziridine which consists of a therapeutically efficaceous quantity of 1-H-2-aziridinecarbonic acid derivative having the formula ##STR1## where R is NH.sub.2 and a pharmaceutically suitable solvent or filler. The pharmaceutical composition possesses a high activity against tumors susceptible to 2-carbamoylaziridine, a wide spectrum of antitumor effect and low toxicity (LD.sub.50 within the range of 3,000 and 3,500 mg/kg. The invention is also a method for treating malignant tumors susceptible to 2-carbamoxylaziridine by administration of 2-carbamoyl-aziridine.

Abstract: Substituted 3-hydrazinopropionates comprising compounds of the general fola: ##STR1## wherein R.sup.1, R.sup.2 =H, an alkyl, a substituted alkyl, hydroxycarbonyl, alkoxycarbonyl, an aryl, an aralkyl, an unsaturated alkyl, a substituted aryl or a substituted aralkyl: ##STR2## wherein R.sup.7, R.sup.8 =H, an alkyl, an unsaturated alkyl, an aralkyl, an aryl, a substituted alkyl,R.sup.9 =OH, an alkoxy, an aralkoxy, an alkyl, an unsaturated alkyl, an aryl, a substituted aryl, an aralkyl;R.sup.4 is --C.tbd.N, --COR.sup.10, wherein R.sup.10 =OR.sup.11, NR.sup.12 R.sup.13, where R.sup.11 is H, an alkyl, an aralkyl and an alkali metal, R.sup.11 and R.sup.12 are each H, an alkyl, an aralkyl, an aryl;R.sup.5, R.sup.6 = an alkyl, an aryl, an aralkyl.

Abstract: A novel pharmaceutical preparation for the treatment of hypertensive disease and myocardial infarction, which comprises as an active ingredient, (1,1-dimethyl-3-oxopyrazolidin-1-io-4-yl)acetate of the following formula: ##STR1## and a pharmaceutically acceptable vehicle.

Abstract: The novel compound according to the invention 3-(2,2,2-trimethylhydrazinium)-propionate has the general formula:(CH.sub.3).sub.3 NNHCH.sub.2 CH.sub.2 COO.2H.sub.2 O.The method for preparing this novel compound comprises passing a solution of 3-(2,2,2-grimethylhydrazinium) alkylpropionate of the formula:X.sup.- (CH.sub.3).sub.3 N.sup.+ NHCH.sub.2 CH.sub.2 COORwherein X is Cl, Br, I, CH.sub.3 SO.sub.4, R is a loawer alkyl, through a column with a strongly-basic anion exchange resin, followed by isolation of the desired product. The growth stimulator for animals and fowl contains the novel compound, i.e. 3-(2,2,2-trimethylhydrazinium)-propionate as the active principle.

Abstract: A pharmaceutical composition for the treatment of cardio-vascular diseases comprising 3-(2,2,2-trimethylhydrazinium) propionate dihydrate of the following formula:(CH.sub.3).sub.3 N.sup.+ NHCH.sub.2 CH.sub.2 COO.sup.- .multidot.2H.sub.2 Oand a pharmaceutically acceptable diluent.